deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT02008396

Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

A Placebo-controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Conditions Social Anxiety in Autistic Adults
Interventions Midomafetamine HCl Placebo Therapy
Updated 20 times since 2017 Last updated: May 23, 2025 Started: Apr 11, 2014 Primary completion: Apr 28, 2017 Completion: Apr 28, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Social Anxiety in Autistic Adults, this trial is completed. The trial is conducted by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center and has accumulated 20 data snapshots since 2014. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Aug 2019 · 10 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Nov 2020 · 12 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~May 2023 · 8 months · monthly snapshot~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Feb 2024 · 6 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Jul 2025 · 7 months · monthly snapshot~Jul 2025 – present · 12 months · monthly snapshot

Change History

20 versions recorded

  1. Jul 2025 — Present [monthly]

    Completed PHASE2

  2. Dec 2024 — Jul 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Dec 2024 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Feb 2024 — Jul 2024 [monthly]

    Completed PHASE2

▶ Show 15 earlier versions

  1. Aug 2023 — Feb 2024 [monthly]

    Completed PHASE2

  2. May 2023 — Aug 2023 [monthly]

    Completed PHASE2

  3. Sep 2022 — May 2023 [monthly]

    Completed PHASE2

  4. Feb 2022 — Sep 2022 [monthly]

    Completed PHASE2

  5. Sep 2021 — Feb 2022 [monthly]

    Completed PHASE2

  6. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE2

  7. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE2

  8. Nov 2020 — Dec 2020 [monthly]

    Completed PHASE2

  9. Nov 2019 — Nov 2020 [monthly]

    Completed PHASE2

  10. Aug 2019 — Nov 2019 [monthly]

    Completed PHASE2

  11. Oct 2018 — Aug 2019 [monthly]

    Completed PHASE2

  12. Jun 2018 — Oct 2018 [monthly]

    Completed PHASE2

  13. Aug 2017 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  14. Feb 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE2

  15. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
  • Lykos Therapeutics
Data source: Lykos Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations